calaspargase pegol-mknl (Asparlas)
calaspargase pegol-mknl is an FDA-licensed reference biologic from Servier Pharmaceuticals LLC. Reference exclusivity, biosimilar lineage, and published patents from official FDA Purple Book records.
0
Biosimilars
0
Interchangeables
0
Listed patents
2018
Reference approved
Reference product
Asparlas calaspargase pegol-mknl
Servier Pharmaceuticals LLC
- Approved
- Dec 20, 2018
- Marketing
- Rx
- Center
- CDER
- Patents
- None listed
Exclusivity & patent cliffs
Approval, exclusivity, and published-patent expiration dates for calaspargase pegol-mknl, in chronological order.
Orphan exclusivity ends
7-year orphan-drug exclusivity window.
25 yr 10 mo ago
Reference approval
Approval date of the reference calaspargase pegol-mknl product.
7 yr 8 mo ago
Frequently asked questions
Are there biosimilars approved for calaspargase pegol-mknl (Asparlas)?
No 351(k) biosimilars or interchangeable biosimilars referencing calaspargase pegol-mknl are listed in the FDA Purple Book yet.
Related FDA reference tools
- FDA Orange BookApproved drugs, generics, therapeutic-equivalence codes, patents, and exclusivity.
- FDA BiosimilarsThe list of FDA-approved biosimilars and interchangeable biosimilars, by reference product.
- 510(k) Predicate DatabaseSearch FDA 510(k) clearances and map predicate-device lineage.
- FDA 483 & Inspection DatabaseFDA Form 483 observations and inspection records by firm, date, and citation.
Explore the full FDA Purple Book
Search every FDA-licensed biologic, biosimilar, and interchangeable with exclusivity timelines and patent records.